Description
The domain expert identified manufacturing complexity as a major barrier, noting that clinical-scale synthetic EV production is unproven. This technical gap blocks translation of any EV-based therapeutic approach.
Source: Debate session sess_SDA-2026-04-02-gap-ev-ad-biomarkers (Analysis: SDA-2026-04-02-gap-ev-ad-biomarkers)